Eradication of Unsightly Blood Vessels — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Eradication of unsightly blood vessels refers to minimally invasive treatments to ablate or collapse superficial dilated blood vessels — primarily spider veins (telangiectasias, 0.1–1 mm diameter), reticular veins (1–4 mm, blue-green), and small varicosities visible through the skin. Three evidence-based treatment modalities are used: sclerotherapy (chemical injection with sodium tetradecyl sulphate or polidocanol), laser therapy (Nd:YAG 1064 nm or pulsed-dye laser 585/595 nm), and intense pulsed light (IPL). Sclerotherapy is the gold standard for leg vessels; laser/IPL is preferred for facial telangiectasias, rosacea, and very fine vessels unsuitable for needling. Significant varicose veins with underlying great saphenous vein (GSV) or small saphenous vein (SSV) reflux must be treated first with endovenous laser ablation (EVLA) or radiofrequency ablation before treating superficial spider veins, as untreated reflux causes rapid recurrence. Spider veins (telangiectasias) affect approximately 40% of women and 20% of men, with the prevalence increasing with age, pregnancy, prolonged standing, oestrogen exposure, and family history. The global market for vascular lesion treatment is substantial: sclerotherapy alone accounts for over 500,000 treatment sessions annually in the United States. Treatment is performed by dermatologists, phlebologists, aesthetic physicians, and vascular surgeons in outpatient clinical settings.

Treatment is indicated for cosmetically bothersome spider veins or reticular veins on the legs causing distress, embarrassment, or discomfort (aching, heaviness, burning, itching). Facial telangiectasias associated with rosacea, port-wine stains, and isolated facial vessels are treated with laser. Pre-treatment duplex ultrasound assessment is mandatory for leg veins to exclude underlying deep venous incompetence or significant reflux at the sapheno-femoral or sapheno-popliteal junction. Treating spider veins in the presence of untreated GSV reflux results in rapid recurrence and wasted treatment. Contraindications include: pregnancy (deferral recommended), acute thrombophlebitis, uncontrolled DVT risk, allergy to the sclerosant, and active skin infection over the treatment area. Patients with CEAP clinical classification C1 (telangiectasias and reticular veins) are the primary candidates for sclerotherapy and laser treatment.

Sclerotherapy: using a fine 30-gauge needle, 0.1–0.5 mL of sclerosant solution (sodium tetradecyl sulphate 0.2–1% or polidocanol 0.5–1%) or foam sclerosant (Tessari technique mixing sclerosant with air 1:4) is injected into each target vessel. The chemical agent irritates the vessel wall endothelium, causing inflammation and eventual fibrosis and vessel obliteration over 4–12 weeks. Multiple injection points are used per session. Class II compression stockings (25–35 mmHg) are applied immediately afterwards and worn for 1–2 weeks. Laser therapy (Nd:YAG 1064 nm): the laser handpiece is applied to the skin over the target vessel; the 1064 nm wavelength selectively targets haemoglobin in the vessel, causing photothermal coagulation and vessel collapse. Each pulse takes milliseconds and covers a 3–10 mm spot. Cooling gel or a sapphire contact-cooling tip minimises epidermal thermal damage. Intense pulsed light (IPL) therapy delivers broad-spectrum light (500–1,200 nm) filtered to target haemoglobin at 530–600 nm, treating facial telangiectasias and diffuse erythema associated with rosacea. The IPL handpiece applies a cool crystal to the skin, and a series of pulses — each 2–5 milliseconds in duration — selectively photocoagulate the target vessels. Multiple passes at 4–6 week intervals achieve progressive clearance. Combined approaches using sclerotherapy for larger reticular veins followed by laser or IPL for the finest superficial vessels maximise overall clearance at fewer total sessions. Ultrasound-guided foam sclerotherapy (UGFS) treats underlying reticular feeder veins that are not visible on the skin surface but drive spider vein formation, addressing the underlying source of venous hypertension.

Sclerotherapy achieves clearance of 50–90% of treated spider veins per session, with most patients requiring 2–4 sessions spaced 4–8 weeks apart for complete clearance. Foam sclerotherapy achieves higher clearance rates than liquid for reticular veins due to better endothelial contact and extended dwell time. Laser therapy achieves 60–90% clearance of facial telangiectasias in 1–3 sessions; the Nd:YAG laser safely treats darker skin types where pulsed-dye laser may cause hyperpigmentation. Results are permanent for treated vessels — obliterated vessels do not reopen. However, new spider veins can develop in previously treated areas due to underlying genetic predisposition, hormonal factors, and venous pressure, making recurrence over years common. Combined treatment (sclerotherapy plus laser) maximises clearance in refractory vessels. Patient satisfaction with spider vein treatment is consistently high when expectations are realistic.

Sclerotherapy adverse effects: bruising at injection sites (nearly universal, resolving within 1–2 weeks); post-sclerotherapy hyperpigmentation (brown staining of overlying skin, occurring in 15–30% due to haemosiderin deposition) — usually fades over 3–12 months but can be permanent; matting (new fine-vessel formation in treated area, 10–15%); urticaria or allergic reaction to sclerosant (rare, under 0.5%); and skin ulceration from perivenous extravasation of sclerosant (rare, under 0.1%). DVT risk after sclerotherapy is very low (under 0.1%) for spider vein treatment but higher with foam sclerotherapy of larger vessels. Laser complications: post-inflammatory hyperpigmentation in darker skin types (Fitzpatrick III–VI), blistering, and paradoxical darkening — all mitigated by appropriate wavelength selection, test patches, and proper skin cooling. All patients are counselled that multiple sessions are typically required for optimal clearance.

After sclerotherapy, compression stockings are worn continuously for 48–72 hours then during waking hours for 1–2 weeks. Walking for 30 minutes immediately after treatment promotes sclerosant dispersion and reduces DVT risk. Hot baths, saunas, and strenuous exercise are avoided for 48 hours. Sun protection (SPF50+) over treated areas minimises hyperpigmentation risk. Treated vessels gradually fade over 4–12 weeks — patients should be counselled not to judge final results for at least 3 months. Laser-treated areas may show immediate darkening (purpura) lasting 1–2 weeks before fading. Follow-up appointments assess treatment response and schedule further sessions as needed. Wearing compression stockings during prolonged standing and avoiding prolonged heat exposure reduces risk of new vessel formation. Most patients return to all normal activities within 24–48 hours of treatment.